Literature DB >> 17062706

Biology of bone cancer pain.

Michael J Goblirsch1, Pawel P Zwolak, Denis R Clohisy.   

Abstract

Bone cancer pain is a devastating manifestation of metastatic cancer. Unfortunately, current therapies can be ineffective, and when they are effective, the duration of the patient's survival typically exceeds the duration of pain relief. New, mechanistically based therapies are desperately needed. Study of experimental animal models has provided insight into the mechanisms that drive bone cancer pain and provides an opportunity for developing targeted therapies. Mechanisms that drive bone cancer pain include tumor-directed osteoclast-mediated osteolysis, tumor cells themselves, tumor-induced nerve injury, stimulation of transient receptor potential vanilloid type 1 ion channel, endothelin A, and host cell production of nerve growth factor. Current and future therapies include external beam radiation, osteoclast-targeted inhibiting agents, anti-inflammatory drugs, transient receptor potential vanilloid type 1 antagonists, and antibody therapies that target nerve growth factor or tumor angiogenesis. It is likely that a combination of these therapies will be superior to any one therapy alone.

Entities:  

Mesh:

Year:  2006        PMID: 17062706     DOI: 10.1158/1078-0432.CCR-06-0682

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  31 in total

1.  The spine instability neoplastic score (SINS) in the assessment of response to radiotherapy for bone metastases.

Authors:  E Gallizia; G Apicella; T Cena; M Di Genesio Pagliuca; L Deantonio; M Krengli
Journal:  Clin Transl Oncol       Date:  2017-06-16       Impact factor: 3.405

2.  Spine Cryoablation: Pain Palliation and Local Tumor Control for Vertebral Metastases.

Authors:  A Tomasian; A Wallace; B Northrup; T J Hillen; J W Jennings
Journal:  AJNR Am J Neuroradiol       Date:  2015-10-01       Impact factor: 3.825

3.  Computed tomography-guided percutaneous microwave ablation combined with osteoplasty for palliative treatment of painful extraspinal bone metastases from lung cancer.

Authors:  Zhigang Wei; Kaixian Zhang; Xin Ye; Xia Yang; Aimin Zheng; Guanghui Huang; Jiao Wang
Journal:  Skeletal Radiol       Date:  2015-06-26       Impact factor: 2.199

4.  Palliative local treatment of bone metastases by 125I seed brachytherapy under DynaCT guidance: single-center experience.

Authors:  Yuan Yao; Zhaonan Li; Dechao Jiao; Xueliang Zhou; Jing Li; Xinwei Han
Journal:  Diagn Interv Radiol       Date:  2021-07       Impact factor: 2.630

5.  Percutaneous image-guided cryoablation of painful metastases involving bone: multicenter trial.

Authors:  Matthew R Callstrom; Damian E Dupuy; Stephen B Solomon; Robert A Beres; Peter J Littrup; Kirkland W Davis; Ricardo Paz-Fumagalli; Cheryl Hoffman; Thomas D Atwell; J William Charboneau; Grant D Schmit; Matthew P Goetz; Joseph Rubin; Kathy J Brown; Paul J Novotny; Jeff A Sloan
Journal:  Cancer       Date:  2012-10-12       Impact factor: 6.860

6.  A novel approach to the use of animals in studies of pain: validation of the canine brief pain inventory in canine bone cancer.

Authors:  Dorothy Cimino Brown; Raymond Boston; James C Coyne; John T Farrar
Journal:  Pain Med       Date:  2008-09-24       Impact factor: 3.750

Review 7.  Animal models of cancer pain.

Authors:  Cholawat Pacharinsak; Alvin Beitz
Journal:  Comp Med       Date:  2008-06       Impact factor: 0.982

Review 8.  Optimal management of bone metastases in breast cancer patients.

Authors:  Mh Wong; N Pavlakis
Journal:  Breast Cancer (Dove Med Press)       Date:  2011-05-02

Review 9.  Metastatic bone pain: treatment options with an emphasis on bisphosphonates.

Authors:  Roger von Moos; Florian Strasser; Silke Gillessen; Kathrin Zaugg
Journal:  Support Care Cancer       Date:  2008-08-06       Impact factor: 3.603

Review 10.  Endothelin receptors and pain.

Authors:  Alla Khodorova; Jean-Pierre Montmayeur; Gary Strichartz
Journal:  J Pain       Date:  2009-01       Impact factor: 5.820

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.